SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs upcoming Q3 earnings report is the main focus, with traders watching guidance, subscriber engagement and advertising growth after a steep share-price decline and recent layoffs and content-leadership changes. Views are split between hopes for a rebound if results or outlook exceed subdued expectations and bets on further losses if growth concerns persist.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is tied to enthusiasm for its Merck-partnered personalized melanoma vaccine after positive Phase 3 topline results, with traders focused on the detailed data presentation at ESMO. Bulls see validation of a broader cancer-vaccine platform and momentum, while bears argue expectations and valuation are stretched and warn of a possible sell-the-news reaction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Traders are citing a reported ClinicalTrials.gov update adding a site to Sareptas ENHANCE Elevidys safety study as a possible trigger for the rebound, though they note the study timeline reportedly slipped. The broader debate centers on whether upcoming DM1 and FSHD data can support a recovery, with some traders pointing to short covering and others stressing that those clinical results remain unproven.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp selloff and fresh low are being linked by traders to plans for a potential Monee listing and the launch of Sea Cloud, alongside concerns about spending and competition in e-commerce. Some see a Monee separation as value-unlocking, while others view the plans and uncertainty around them as a reason to sell; claims of further undisclosed bad news remain speculation.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs earnings beat and higher outlook have been met with a sharp selloff, prompting traders to question why strong demand and orders are not lifting the shares. The debate centers on rising costs, weaker cash conversion and an insurance loss, while some investors view the reaction as excessive given the improved guidance.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention after its quarterly earnings beat and improved cash-flow outlook failed to prevent a sharp selloff, as traders focused on narrowed full-year profit guidance with no increase to its midpoint. Some see the new buyback and cash generation as support for the shares, while others argue the outlook disappointed despite the strong quarter.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving the sharp rally, with traders viewing the cash proceeds as a potential balance-sheet and strategic reset. Others argue the divestiture removes a significant revenue stream and leaves concerns about debt and weakness in the remaining business; the transaction is still pending approval and closing.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel data in progressive MS and additional BRIUMVI results, with commercial growth and a future subcutaneous formulation also part of the bullish case. Traders are anticipating a catalyst-driven move, though some caution that the azer-cel results remain uncertain and complain that the shares have struggled to break out of a trading range.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

A sharp COMP rally has sparked breakout talk, with traders pointing to rising momentum, chart patterns, and the tokens limited supply; others remain skeptical, calling it a volatile bounce and questioning whether gains can hold.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

RAP-219s Phase 2 trial in bipolar mania met its primary and secondary endpoints, prompting bullish trading and analyst optimism, including an upgrade. The community is divided over the modest placebo-adjusted benefit and concerns about agitation and discontinuations; the initial surge faded as traders debated whether the data justify further upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for...

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

BioMarin Appoints Cara Bauer as Chief People Officer

BioMarin Appoints Cara Bauer as Chief People Officer BioMarin Appoints Cara Bauer as Chief People OfficerPR NewswireSAN RAFAEL, Calif., Oct. 5, 2026Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology IndustriesAppointment Effective Oct. 5...

BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress

BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual CongressPR...

FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of DirectorsPR NewswireSAN RAFAEL, Calif., Sept...

BioMarin Reports Positive Phase 3 Results For VOXZOGO

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) on Wednesday announced positive Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, with the study meeting its primary endpoint and all secondary efficacy endpoints...

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Martin Shkreli called RARE stock “very cheap” and said BioMarin and other rare-disease drugmakers should explore acquiring Ultragenyx.</li><li>RARE stock's selloff followed the failure of Apazunersen in a Phase 3 Angelman syndrome trial, where the drug missed both its primary and secondary endpoints.</li><li>Analysts said the investment case now depends on commercial execution, margin expansion, and upcoming pipeline catalysts.</li></ul><p>Shares of Ultragenyx Pharmaceutical (RARE) suffered their worst trading day on record and closed at an all-time low on Thursday after its Angelman syndrome treatment failed a key trial, prompting sweeping Wall Street target cuts and takeover speculation from former pharma executive Martin Shkreli.</p><p><a href="https://stocktwits.com/symbol/RARE">RARE stock</a> plunged about 44% to $14.85 on Thursday, wiping out nearly half its value in one session.</p><h2 class="st-heading-2"><strong>Shkreli Floats BioMarin Buyout&nbsp;</strong></h2><p>“$RARE is very cheap,” Shkreli&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2095490113857851515">said on X</a>. He argued that BioMarin Pharmaceutical (BMRN) and other rare-disease companies “should explore buying the company.” Shkreli, widely known as “Pharma Bro,” also claimed that the setback was foreseeable, saying “everyone and their brother with three months of med school/Shkreli training knew this trial would fail.”</p><p>BioMarin and Ultragenyx both develop and commercialize treatments for genetically defined rare diseases, with overlap in metabolic disorders, enzyme-replacement therapies, gene therapy and the specialist physicians they serve.&nbsp;</p><p>Ultragenyx shares crashed after its Phase 3 Aspire trial of Apazunersen, formerly GTX-102, failed both its primary and secondary endpoints. Patients receiving the drug showed no meaningful improvement over the control group in cognition or across a broader measure of Angelman symptoms.&nbsp;</p><p>Apazunersen was designed to activate a normally silent copy of the UBE3A gene. Angelman syndrome is a rare genetic brain disorder that can cause cognitive and movement impairments, seizures, balance problems and severe speech limitations. Ultragenyx estimates it affects about 60,000 people in accessible markets, with no approved treatment for its underlying cause.&nbsp;</p><p>The drug’s safety profile remained consistent with its Phase 1/2 program, but Ultragenyx said it will now assess the program’s future and implement “significant expense reductions.”&nbsp; The company said it will refocus on its expanding commercial portfolio, including recently approved Genglycos for glycogen storage disease type Ia, the potential approval of UX111 for Sanfilippo syndrome and geographic expansion of existing products.&nbsp;</p><h2 class="st-heading-2"><strong>Wall Street Slashes RARE Targets&nbsp;</strong></h2><p>Wall Street stripped the Angelman program from valuation models after the failure. RBC said the lack of numerical disclosure and limited positive framing suggested the drug may have produced no efficacy signal, while cautioning against automatically applying that conclusion to Ionis Pharmaceuticals’ (IONS) competing program due to differences in the molecules and dosing.</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col><col><col></colgroup><tbody><tr><td>Firm</td><td>Rating Action</td><td>New Target</td><td>Previous Target</td><td>Target Cut</td><td>Upside From Current Levels</td></tr><tr><td>Jefferies</td><td>Maintained 'Buy'</td><td>$28</td><td>$77</td><td>64%</td><td>89%</td></tr><tr><td>TD Cowen</td><td>Maintained 'Buy'</td><td>$18</td><td>$49</td><td>63%</td><td>21%</td></tr><tr><td>Cantor Fitzgerald</td><td>Maintained 'Overweight'</td><td>$33</td><td>$103</td><td>68%</td><td>122%</td></tr><tr><td>Wedbush</td><td>Maintained 'Neutral'</td><td>$23</td><td>$30</td><td>23%</td><td>55%</td></tr><tr><td>RBC Capital</td><td>Cut to 'Sector Perform' from 'Outperform'</td><td>$19</td><td>$40</td><td>53%</td><td>28%</td></tr><tr><td>Canaccord</td><td>Maintained 'Buy'</td><td>$37</td><td>$83</td><td>55%</td><td>149%</td></tr><tr><td>BofA</td><td>Cut to 'Neutral' from 'Buy'</td><td>$20</td><td>$48</td><td>58%</td><td>35%</td></tr><tr><td>Morgan Stanley</td><td>Cut to 'Equal Weight' from 'Overweight'</td><td>$18</td><td>$74</td><td>76%</td><td>21%</td></tr></tbody></table></figure></div><p>TD Cowen called the failure unfortunate but not surprising given already-low expectations. Meanwhile, Jefferies said the outcome was surprising but added that Ultragenyx’s commercial franchise and broader potential was intact. Cantor Fitzgerald said it understood the trial’s risks but had hoped for better results.</p><p>Wedbush removed Apazunersen from its estimates and revised its spending assumptions. Morgan Stanley said the investment debate will now shift toward commercial execution, margin expansion and the remaining pipeline, warning that a strategic reset will take time.&nbsp;</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About RARE?</strong></h2><p>On Stocktwits, retail sentiment for RARE jumped to ‘extremely bullish’ from ‘neutral’ levels a week ago amid a 9,200% surge in message volumes over the past week. The ticker’s watcher base has also jumped nearly 40% in a month and 27% in a week.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/rare_ss_4720fba7ea.png" alt="rare ss.png" width="643" height="346"><figcaption>RARE sentiment and message volume as of September 4 | Source: Stocktwits</figcaption></figure><p>One user&nbsp;<a href="https://stocktwits.com/LQQKER_INSIDER/message/663566322">said</a>, “all things considered, the call options appear cheap and I'd say the most prudent way to play this if you want to protect yourselves should it experience another big leg down instead. I'll give this a speculative BUY rating.”</p><p><stembedurl>https://stocktwits.com/LQQKER_INSIDER/message/663566322</stembedurl></p><p>Another user said, “$RARE overreacting. They still generating $740 revenue and have 5 commercialized drugs and q drug to be launched in Q4 and 1 drug has a PDUFA on 9/19/2026. Also, institutional ownership is 128%. This will open &gt;$22|</p><p><stembedurl>https://stocktwits.com/SeniorVip/message/663510523</stembedurl></p><p>RARE stock has declined 53% over the past year.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-nvidia-hugging-face-no-brainer-wall-street-threat-openai-anthropic/cZswMddRJwJ">Michael Burry Calls Nvidia-Hugging Face Deal A ‘No-Brainer’ — Wall Street Sees New Threat For OpenAI And Anthropic&nbsp;</a></p>

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout

Ionis Pharmaceuticals Inc

Ultragenyx Pharmaceutical Inc

SPDR S&P Biotech ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Stocktwits Polls

$BMRN 
 
Raymond James upgraded this to Strong Buy from Outperform on Monday, with a 109 dollar target, after meeting with management. 
 
That target is nearly double the recent price, and the stock has slid about 16% in the past month. Q2 revenue was 990 million dollars, up 20% year over year, and Voxzogo guidance was raised to at least 1 billion dollars for 2026.

Krypton Research

$BMRN I put a stop loss at $54. I’m not playing this stupid ass game. This stock has been screwed recently

AuStocks

$BMRN hoping for 4-5 bucks on this bounce then a retest around earnings , follows by a steady climb to low $80's . If it retests now it will go lower ..

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMRN Biomarin Pharmaceutical Inc. - Registered Shares

Fundamentals

Latest BMRN News